## Medicines and Healthcare Products Regulatory Agency

CERTIFICATE NUMBER : *UK MIA 17901 Insp GMP/GDP/IMP 17901/10117-0043* 

# CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

#### Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of United Kingdom confirms the following:

The manufacturer : ASTRAZENECA UK LIMITED

Site address: SILK ROAD BUSINESS PARK, MACCLESFIELD, SK10 2NA, United Kingdom


Has been inspected under the national inspection programme in connection with manufacturing authorisation no. *UK MIA 17901* in accordance with Art. 40 of Directive 2001/83/EC transposed in the following national legislation:

The Human Medicines Regulations 2012 (SI 2012/1916)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2020-02-10**, it is considered that it complies with:

• The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC<sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.



<sup>&</sup>lt;sup>1</sup> The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

<sup>&</sup>lt;sup>2</sup> Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>&</sup>lt;sup>3</sup> These requirements fulfil the GMP recommendations of WHO.

### Part 2

### **Human Medicinal Products**

1.1	NUFACTURING OPERATIONS Sterile products
1.1	1.1.1 Aseptically prepared (processing operations for the following dosage forms)
	1.1.1.5 Solids and implants Special Requirements 7 Other: LHRH Agonist ( Zoladex)(en)
	1.1.1.6 Other: LHRH Agonist ( Zoladex)(en)
	1.1.2 Terminally Sterilised (processing operations for the following dosage forms)
	1.1.2.3 Small volume liquids
	1.1.3 Batch certification
1.2	Non-sterile products
	1.2.1 Non-sterile products (processing operations for the following dosage forms)
	1.2.1.1 Capsules, hard shell
	1.2.1.5 Liquids for external use
	1.2.1.6 Liquids for internal use
	1.2.1.13 Tablets
	1.2.1.17 Other: Antioestrogen (Nolvadex)(en)
	1.2.2 Batch certification
1.5	Packaging
	1.5.1 Primary Packaging
	1.5.1.1 Capsules, hard shell
	1.5.1.5 Liquids for external use
	1.5.1.6 Liquids for internal use
	1.5.1.8 Other solid dosage forms
	1.5.1.13 Tablets
	1.5.2 Secondary packaging
1.6	Quality control testing
	1.6.1 Microbiological: sterility
	1.6.2 Microbiological: non-sterility
	1.6.3 Chemical/Physical
L	

2 IMPORTATION OF MEDICINAL PRODUCTS		
2.1	Quality control testing of imported medicinal products	
	2.1.1 Microbiological: sterility	
	2.1.2 Microbiological: non-sterility	
	2.1.3 Chemical/Physical	
2.2	Batch certification of imported medicinal products	
	2.2.1 Sterile products	
	2.2.1.1 Aseptically prepared	
	2.2.1.2 Terminally sterilised	
	2.2.2 Non-sterile products	
2.3	Other importation activities	
	2.3.1 Site of physical importation	
	2.3.2 Importation of intermediate which undergoes further processing	



Name and signature of the authorised person of the Competent Authority of United Kingdom

.....

Confidential
Medicines and Healthcare Products Regulatory Agency
Tel:Confidential
Fax: Confidential